Evidence map›Paper›PMID 40420192›Full record

ArticleJournal of experimental & clinical cancer research : CR2025

Tumour-associated macrophage infiltration differs in meningioma genotypes, and is important in tumour dynamics.

Ting Zhang, Claire L Adams, Gyorgy Fejer, Emanuela Ercolano, Jonathan Cutajar, Juri Na, Felix Sahm, C Oliver Hanemann

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ting ZhangPeninsula Medical School, Faculty of Health, University of Plymouth, Plymouth, Devon, PL6 8BU, UK.
Claire L AdamsPeninsula Medical School, Faculty of Health, University of Plymouth, Plymouth, Devon, PL6 8BU, UK.
Gyorgy FejerSchool of Biomedical Sciences, Faculty of Health, University of Plymouth, Plymouth, Devon, PL6 8BU, UK.
Emanuela ErcolanoPeninsula Medical School, Faculty of Health, University of Plymouth, Plymouth, Devon, PL6 8BU, UK.
Jonathan CutajarDerriford Hospital, University Hospitals Plymouth NHS Trust, Plymouth, Devon, PL6 8DH, UK.
Juri NaPeninsula Medical School, Faculty of Health, University of Plymouth, Plymouth, Devon, PL6 8BU, UK.
Felix SahmDepartment of Neuropathology, Institute of Pathology, University Hospital Heidelberg, 69120, Heidelberg, Germany.
C Oliver HanemannPeninsula Medical School, Faculty of Health, University of Plymouth, Plymouth, Devon, PL6 8BU, UK. oliver.hanemann@plymouth.ac.uk.

Funding

Brain Tumour Research Hanemann
6 · The paper itself

Abstract

backgroundMeningiomas are the most common primary intracranial tumours, with clinical behaviours ranging from benign to highly aggressive forms. The World Health Organisation classifies meningiomas into various grades, guiding prognosis and treatment. While surgery is effective for low-grade meningiomas, certain grade 1 tumours, as well as grade 2, 3, and recurrent cases are more aggressive and require new therapeutic approaches. Immunotherapy shows promise, with early-stage clinical trials demonstrating encouraging results. The tumour microenvironment (TME), particularly tumour-associated macrophages (TAMs), plays a pivotal role in tumour progression. TAMs influence tumour growth, metastasis, and immune evasion. However, their role in meningiomas, especially in relation to genomic mutations, remains poorly understood. Understanding how genetic alterations affect the TME is critical for developing targeted immunotherapies.

methodsThis study employed multiplex immunohistochemistry and bulk RNA sequencing to explore immune infiltration in genetically stratified meningioma tissues and matched three-dimensional (3D) spheroid models. We compared immune cell populations across parental tissues, two-dimensional (2D) monolayer cultures, and 3D spheroid models. In addition, co-culture experiments were conducted, introducing M2-polarised macrophages derived from peripheral blood mononuclear cells to study the interactions between immune cells and tumour cells.

resultsOur findings revealed significant differences in the immune infiltration patterns associated with specific genotypes and methylation classes, especially M2-like TAMs. Notably, the 3D spheroid models more closely replicated the TME observed in parental tissues compared to traditional 2D monolayer cultures, offering a superior platform for immune infiltration studies. Furthermore, co-culture experiments demonstrated that M2-polarised macrophages could effectively infiltrate tumour cells, promote tumour cell proliferation while inhibiting invasion, suggesting IL-6-mediated signalling in tumour progression.

conclusionsThese findings suggest that 3D co-culture models offer an excellent system for studying the role of immune cells, specifically TAMs, in meningioma progression. By providing a more accurate representation of the TME, these models can help identify novel immunotherapy strategies aimed at modulating the immune response within meningiomas. Ultimately, this approach may improve therapeutic outcomes and quality of life for patients with meningioma by enhancing the effectiveness of existing treatments or by offering new immunotherapeutic options.

Indexed as

MacrophagesMeningeal NeoplasmsMeningiomaTumor-Associated MacrophagesFemaleGenotypeHumansMaleTumor Microenvironment3D co-culture modelGenotypeMacrophage-to-microglia ratioMeningiomaMethylation classTumour-associated macrophagesTumour microenvironmentTumour progression

Identifiers

PMID40420192
PMCPMC12107748

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.